01 / THE CANCER TRENDS
The age shift is real.
The American Cancer Society’s 2026 analysis shows different trajectories across U.S. age groups.Colorectal cancer statistics, 2026 ↗
| Age | Average annual change 2013–2022 | Cases per 100,000 people/year 2018–2022 |
|---|---|---|
| 20–49 | +3.0%Increasing | 13.1 |
| 50–64 | +0.4%Increasing | 68.0 |
| 65+ | −2.5%Decreasing | 153.1 |
ACS, Tables 2–3. Age-adjusted, reporting-delay-adjusted incidence; appendix cancers excluded. A 2026 publication reports earlier registry years. These are population rates, not personal predictions.
A 3% annual increase does not mean a 3% annual chance of cancer. Older adults still have higher absolute rates. The broad 20–49 band also should not be treated as the specific risk at age 45.
Diagnoses before age 50 occur at ages 45–49—the group already eligible for routine screening.Colorectal cancer statistics, 2026 ↗
Colorectal cancer now ranks first among causes of cancer death in U.S. adults under 50.Colorectal cancer statistics, 2026 ↗
Explore birth-cohort findings, denominators, and limitations ↗
02 / BEFORE CANCER
Precancer is not waiting for retirement.
First screening colonoscopies at Kaiser Permanente Northern California, 2021–2024; diagnostic, higher-risk, and incomplete examinations were excluded.Screening colonoscopy yield study ↗
| Finding | Ages 45–49 4,380 people | Ages 50–54 7,651 people |
|---|---|---|
| Any adenoma | 1,551 (35.4%) | 3,121 (40.8%) |
| Advanced adenoma | 165 (3.8%) | 314 (4.1%) |
| Advanced serrated lesion | 65 (1.5%) | 137 (1.8%) |
| Colorectal cancer | 3 (0.1%) | 9 (0.1%) |
Published rounding; categories overlap, so do not add percentages. Advanced findings did not differ significantly by age; equivalence is not established. These screening yields do not measure national prevalence or trends.
“Advanced” does not mean cancer. An adenoma is a precancerous polyp. Advanced adenomas have higher-risk size or microscopic features; advanced serrated lesions are another precursor category. Not every precancer progresses to cancer.Screening colonoscopy yield study ↗NCI evidence ↗
03 / READING THE DATA CORRECTLY
Two questions. Different evidence.
Are younger adults being diagnosed with more cancer? Yes, the age-specific registry trends support that conclusion. Do those trends establish that advanced precancer is becoming more common at the same rate? No. Cancer diagnoses and precursor findings are different endpoints.
The defensible message: colorectal cancer is rising in younger adults, and clinically important precancer is already found in people aged 45–49. A claim that advanced precancer is also increasing nationally over time requires its own evidence.
What do studies of polyp trends actually show?
A U.S. pathology study examined 2,910,174 colonoscopies from 2008–2020. Serrated adenoma detection increased, while tubular adenoma detection decreased; precursor and cancer trends did not move uniformly together.Polyp trends study ↗
This analysis did not establish a national trend for the specific combined endpoint “advanced precancer.” Changing recognition of lesions, the people referred for colonoscopy, and study definitions also matter when comparing detection rates.
Our interpretation: evidence of an important screening yield at age 45 is sufficient to explain why screening matters now. It should not be relabeled as proof of an increase over time.
Could more screening explain some of the recent increase in diagnoses?
Yes. After screening eligibility expanded in 2021, a 2026 SEER analysis found particularly rapid growth in early-stage diagnoses at ages 45–49.Age and stage trends study ↗
| Diagnoses | Annual change |
|---|---|
| All stages | +14.38% |
| Early stage | +32.14% |
| Late stage | +3.29% |
For comparison, all-stage diagnoses in this age group increased 1.31% annually during 2004–2019. The authors interpret the recent acceleration as suggesting increased detection after screening expansion.
Our interpretation: a short post-guideline trend cannot separate changing underlying risk from more testing or pandemic-related disruptions. Rising late-stage diagnoses merit attention, but do not by themselves establish the cause of the rise. These figures are not a measured effect of colonoscopy on future cancer outcomes.
Burus & Semprini, online August 25, 2026. Numerical findings verified against the primary abstract; full methods and stage definitions were not independently reviewed.
04 / WHY START ON TIME?
The opportunity comes before symptoms.
Screening looks for disease in people who feel well. Polyps and cancer may cause no symptoms. Waiting for bleeding or pain changes the task from routine screening to evaluating a possible problem.CDC symptom guidance ↗
Starting at 45 reflects a balance of benefits and harms. The U.S. Preventive Services Task Force finds a moderate net benefit for ages 45–49, drawing on epidemiology, empirical studies, and modeling. The American Cancer Society reaffirmed age 45 in 2026.Screening guideline ↗Screening guideline ↗
Colonoscopy can examine the colon directly and remove detected precancerous growths during the same examination. That is the preventive opportunity behind this campaign’s preference for high-quality colonoscopy when you are due, medically appropriate, willing, and have timely access.NCI evidence ↗
Preparation, sedation, and a ride home require planning. Colonoscopy can miss lesions and can cause bleeding, perforation, or sedation complications. Stool tests remain guideline-supported options; they require repeat testing, and a positive result requires colonoscopy. Completing that follow-up can also lead to precancer removal.Screening guideline ↗NCI evidence ↗
Compare the screening options →05 / YOUR NEXT STEP
Make the plan fit your history.
45–75
Average risk
If you have not started screening, arrange it now. If already screened, follow the interval appropriate to your test and results. A normal, high-quality colonoscopy commonly allows 10 years; polyp findings can change that schedule.Screening guideline ↗
Under 45
Check your risk
Routine screening usually begins at 45 for people at average risk. A close relative with colorectal cancer or an advanced polyp, an inherited syndrome, inflammatory bowel disease, or your own polyp history may call for earlier testing or a different follow-up plan. Bring relatives’ diagnoses and ages at diagnosis to your clinician.Screening guideline ↗NCI evidence ↗
Any age
Symptoms need evaluation
Rectal bleeding, persistent changes in bowel habits, unexplained iron-deficiency anemia, unexplained weight loss, or ongoing abdominal pain warrant medical assessment. These symptoms have many possible causes. Do not wait for your screening birthday or let a negative screening test replace a diagnostic evaluation.CDC symptom guidance ↗
For ages 76–85, screening is individualized according to health, prior screening, and preferences. Major guidelines advise stopping routine screening after 85.Screening guideline ↗Screening guideline ↗
“I’m 45. Am I due for screening—and is colonoscopy right for me?”A useful way to start the conversation.
06 / CHECK THE SOURCES
The numbers, with their context.
A focused evidence review, not a formal systematic review. Dates, populations, and endpoints remain attached to their findings.
- 01Siegel et al. · Colorectal cancer statistics, 2026 ↗
CA Cancer J Clin. 2026;76:e70067. Registry surveillance; Tables 2–3 and screening discussion.
ACS one-page facts ↗ - 02Lee et al. · Screening colonoscopy yields at ages 45–49 ↗
JAMA. 2025;334:449–452. doi:10.1001/jama.2025.7494. Table 2. Single-system observational cohort.
- 03U.S. Preventive Services Task Force · Screening recommendation ↗
2021 final recommendation. Ages, intervals, options, benefit–harm assessment, and modeling context.
- 04American Cancer Society · 2026 guideline summary ↗
Reaffirms routine screening from age 45 for average-risk adults.
Guidance on higher-risk histories ↗ - 05Sonnenberg et al. · Trends of colonic neoplasia ↗
Dig Dis Sci. 2022;67:4702–4707. doi:10.1007/s10620-021-07358-8. Pathology-based observational analysis; 2008–2020. Abstract verified; not an estimate of national advanced-precancer incidence.
- 06Burus & Semprini · Age and stage trends after screening expansion ↗
Am J Prev Med. Online August 25, 2026. doi:10.1016/j.amepre.2026.108568. SEER analysis; abstract-level review. Authors report no competing interests.
- 07CDC · Symptoms of colorectal cancer ↗
Updated June 17, 2026. Symptoms and the importance of assessment.
- 08National Cancer Institute · Screening tests and polyps ↗
Mechanisms, precancer removal, risk factors, and test limitations. Current screening ages are sourced separately to the USPSTF and ACS.
Study disclosures and review limits
The ACS statistics authors are ACS employees, paid through ACS funds. ACS receives outside grants for other work; authors reported no conflicts.
Lee et al. disclose grants involving NCI, PCORI, Medial Research, and Freenome, plus a Geneoscopy advisory role then uncompensated. These author disclosures do not establish study sponsorship.
The polyp-trend and age/stage studies above were reviewed at abstract level; detailed funding information unavailable in those abstracts is not represented as “no funding.” None of these age-pattern or screening-yield studies directly compares colonoscopy with Cologuard for long-term prevention in 45–49-year-olds.
This independent campaign is not endorsed by the named research organizations. Individual decisions should account for your medical history, procedure risks, preferences, and access.